1. Introduction {#sec1-jcm-09-01974}
===============

Abdominal aortic aneurysms (AAA) are segmental dilatations of the abdominal aorta measuring 50% greater than the proximal normal segment, or \>3 cm in maximum diameter \[[@B1-jcm-09-01974],[@B2-jcm-09-01974]\]. Screening programs launched in different populations reported the prevalence of AAA between 4% and 8% in general population of men aged 65--80 years \[[@B3-jcm-09-01974]\] and lower (0.45%) in Asians \[[@B4-jcm-09-01974]\]. AAA rupture is responsible for 0.3--0.4% of all death cases and approximately 1% of deaths among men above 65 years globally, causing 130,000 to 180,000 fatalities per year \[[@B5-jcm-09-01974]\]. Although mortality of AAA is decreasing in the 21st Century in many countries including United States and United Kingdom (mostly due to introduction of more advanced endovascular and open surgery repair techniques and better risk factor management), in other countries (Hungary, Romania), AAA mortality is still increasing \[[@B6-jcm-09-01974],[@B7-jcm-09-01974],[@B8-jcm-09-01974],[@B9-jcm-09-01974]\].

The specific mechanism initiating and leading to progression of AAA has not yet been elucidated; however, AAA development has been associated with a variety of infections like brucellosis, salmonellosis and tuberculosis, trauma and connective tissue disorders, Takayasu disease and Marfan syndrome. Identified risk factors for aneurysm development include older age, male gender, cigarette smoking, obesity, dysregulation of lipid levels, hypertension \[[@B2-jcm-09-01974],[@B10-jcm-09-01974],[@B11-jcm-09-01974],[@B12-jcm-09-01974]\] and genetic predisposition \[[@B13-jcm-09-01974],[@B14-jcm-09-01974],[@B15-jcm-09-01974],[@B16-jcm-09-01974]\].

Patients with AAA may report nonspecific symptoms like abdominal and back pain; however, in many cases disease progress is asymptomatic. The prolonged course of asymptomatic phase of AAA provides a relatively long diagnostic window before rupture \[[@B17-jcm-09-01974]\]. Despite many studies targeting circulatory biomarkers of AAA, there is still lack of robust molecular methods able to classify affected individuals with satisfactory precision \[[@B18-jcm-09-01974],[@B19-jcm-09-01974],[@B20-jcm-09-01974]\].

MiRNA-dependent regulation of gene expression emerged as a new tool providing novel opportunities in diagnosis of AAA. MiRNAs are approximately 18--25 nucleotides long, non-coding and single-stranded RNAs, which exhibit gene expression regulating effect by binding to mRNA. The pairing effect of miRNA-mRNA interactions predominantly inhibits gene expression by repression of translation, destabilization and cleavage of mRNA \[[@B21-jcm-09-01974],[@B22-jcm-09-01974]\]. Currently miRNAs are a particularly intensively studied with promising preliminary results opening door to novel diagnostic and treatment approaches \[[@B23-jcm-09-01974]\].

Large studies comparing miRNA and gene expression patterns in patients with AAA and healthy individuals may provide novel biomarkers with good discriminative value improving our diagnostic capability of detecting aneurysm, its rates of progression and complications; however, their introduction to clinical practice requires further investigations \[[@B24-jcm-09-01974],[@B25-jcm-09-01974],[@B26-jcm-09-01974],[@B27-jcm-09-01974]\].

Although differential expression of miRNAs in human AAA cases was reported in abdominal aortic tissue, whole blood, serum and plasma samples, deregulation of miRNA expression in PBMCs (peripheral blood mononuclear cells) was not extensively studied.

In the present study, we applied next generation sequencing to analyze miRNA and gene expression in PBMCs of AAA patients and healthy volunteers with a goal to find the most capable miRNA and gene expression biomarkers of AAA and to research a potential role of identified biomarkers in pathogenesis of AAA.

The study design, methodology, article structure and language have been inspired by our previous studies regarding deregulation of miRNA regulatory network in lower extremities arterial disease \[[@B28-jcm-09-01974]\] and chronic venous disease \[[@B29-jcm-09-01974]\].

2. Materials and Methods {#sec2-jcm-09-01974}
========================

2.1. Study Participants Characteristics {#sec2dot1-jcm-09-01974}
---------------------------------------

The study was performed in accordance with the Declaration of Helsinki. The study design was approved by the Ethics Committee of Medical University of Lublin (decision No. K × 10−254/341/2015). Inclusion was carried out between February 2016 and May 2017. Twenty eight patients hospitalized due to intrarenal true AAA in Independent Public Clinical Hospital No. 1 in Lublin were included in the AAA group. All patients underwent pre-operative aneurysm surveillance, which included duplex ultrasonography and contrast enhanced spiral computed tomography with volume-rendered reconstructions.

Nineteen healthy and non-smoking volunteers were included in the control group. Control subjects have not shown presence of abdominal aorta dilatation and abnormalities during duplex ultrasound scanning.

Informed and signed consent was obtained from all study participants. All participants were asked about smoking habits and medical history to establish exclusion criteria, which included presence of inflammatory aneurysm, false aneurysm, thoracic aorta aneurysm, isolated popliteal or iliac artery aneurysm, aortic and/or arterial dissection, stroke, transient ischemic attack (TIA), myocardial infarction, diabetes mellitus type I, symptomatic peripheral arterial disease (ankle brachial index \< 0.8), connective tissue disorders including rheumatoid disease, impaired hepatic or renal function, corticoid therapy, infection within previous 6 weeks, recent deep venous thrombosis (less than 1 year), pulmonary embolism, inflammatory and/or infectious disease and cancer. Detailed characteristics of case and control group are presented in [Table 1](#jcm-09-01974-t001){ref-type="table"}. Application of exclusion criteria enabled to include healthy individuals to control group; however, statistically significant differences in age, body mass index (BMI), smoking habits, and sex distribution were noticed when compared to AAA group ([Table 1](#jcm-09-01974-t001){ref-type="table"}). Construction of AAA and control groups is described in detail in [Appendix A](#app2-jcm-09-01974){ref-type="app"}.

2.2. Study Material Preparation and Sequencing {#sec2dot2-jcm-09-01974}
----------------------------------------------

The procedure of study material preparation and sequencing was conducted as previously described in \[[@B28-jcm-09-01974]\].

Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood specimens using density gradient centrifugation with Gradisol L reagent (Aqua-Med, Łódź, Poland). Proportions of white blood cells subpopulations in AAA group were obtained from venous blood morphology analysis results and were presented in [Figure S1](#app1-jcm-09-01974){ref-type="app"}.

Small RNA fractions (for miRNA expression analysis) were isolated from PBMCs specimens of twenty eight AAA patients and nineteen control subjects using MirVana microRNA Isolation Kit (Ambion, Austin, TX, USA).

Total RNA specimens (for transcriptome analysis) were isolated from PBMCs samples of seven randomly selected AAA patients and seven randomly selected controls using TRI Reagent Solution (Applied Biosystems, Foster City, CA, USA).

Small RNA and transcriptome libraries were prepared using Ion Total RNA-Seq Kit v2, Magnetic Bead Cleanup Module kit, Ion Xpress RNA-Seq Barcode 01-16 Kit and sequenced on Ion 540 chips (all Life Technologies, Carlsbad, CA, USA) using Ion S5 XL System (Thermo Fisher Scientific, Waltham, MA, USA). Raw sequences of small RNA and transcriptomic libraries were aligned to 2792 human miRNAs from miRBase v21 (<http://www.mirbase.org>) and to 55,765 genes of hg19 human genome, respectively.

2.3. Statistical and Bioinformatical Analysis {#sec2dot3-jcm-09-01974}
---------------------------------------------

Detailed description of methodology applied to statistical and bioinformatical analysis was provided in our previous study \[[@B28-jcm-09-01974]\].

The differences of AAA and control groups in age and BMI were evaluated using two-sided Mann--Whitney *U* test (wilcox.test function in R), and in sex and smoking using Fisher's exact test (fisher.test function in R).

Statistical analysis of miRNA expression data (resulted from sequencing of small RNA libraries) and gene expression data (resulted from sequencing of transcriptome libraries) was performed using R environment (version 3.5.2, <https://www.r-project.org>). Analysis was conducted on biological replicates. Differential expression analysis was performed using DESeq2 and UVE-PLS (uninformative variable elimination by partial least squares) \[[@B30-jcm-09-01974]\] methods implemented in DESeq2 1.18.1 (<https://bioconductor.org/packages/release/bioc/html/DESeq2.html>) \[[@B31-jcm-09-01974]\] and plsVarSel 0.9.3 (<https://cran.r-project.org/web/packages/plsVarSel/index.html>) \[[@B32-jcm-09-01974]\] packages, respectively. MiRNA and gene transcripts found by DESeq2 method with *p* value \< 0.05 after adjustment by Benjamini--Hochberg false discovery rate were considered as statistically significant. UVE-PLS analysis was performed for miRNA and gene expression data using 3 and 2 PLS components, respectively. UVE-PLS analysis was executed with 1,000 iterations and default cut-off threshold.

Visualizations including Venn diagrams, heat-maps and PCA (principal component analysis) plots were prepared using VennDiagram 1.6.20 (<https://cran.r-project.org/web/packages/VennDiagram/index.html>) \[[@B33-jcm-09-01974]\], pheatmap 1.0.10 (<https://cran.r-project.org/web/packages/pheatmap/index.html>) and ggplot2 3.2.1 (<https://cran.r-project.org/web/packages/ggplot2/index.html>) packages, respectively.

Receiver operating characteristics (ROC) analysis was performed using pROC package version 1.12.1 (<https://cran.r-project.org/web/packages/pROC/index.html>) \[[@B34-jcm-09-01974]\]. Spearman rank correlation test implemented in Hmisc package 4.4-0. (<https://cran.r-project.org/web/packages/Hmisc/index.html>) was used to perform correlation analysis.

In order to evaluate the diversity of cell subpopulation in PBMCs specimens, the deconvolution of gene expression data was performed using "quanTIseq" \[[@B35-jcm-09-01974]\] and "MCPcounter" \[[@B36-jcm-09-01974]\] methods implemented to immunedeconv 2.0.0 package (<https://rdrr.io/github/grst/immunedeconv/>) \[[@B37-jcm-09-01974]\].

Interactions between selected miRNAs and genes were identified using multiMiR package 1.2.0 (<https://bioconductor.org/packages/release/bioc/html/multiMiR.html>) \[[@B38-jcm-09-01974]\]. Obtained interactions formed a regulatory network, which was presented using Cytoscape v3.5.1 software (<https://cytoscape.org/>) \[[@B39-jcm-09-01974]\].

Functional analysis was performed for genes included in the network using DAVID (Database for Annotation, Visualization and Integrated Discovery) 6.8 database (<https://david.ncifcrf.gov/>) \[[@B40-jcm-09-01974],[@B41-jcm-09-01974]\] and it's supporting resources: KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway maps, the Reactome Database of Signaling Pathways, GAD (Genetic Association Database) and GO (Gene Ontology). As a background, default whole *Homo sapiens* genome was applied. All associated terms of KEGG, Reactome and GAD categories were harvested as well as associated GO terms with Expression Analysis Systematic Explorer (EASE) score \< 0.05.

3. Results {#sec3-jcm-09-01974}
==========

The summary of research process is presented on [Figure 1](#jcm-09-01974-f001){ref-type="fig"}.

3.1. Study Population Analysis {#sec3dot1-jcm-09-01974}
------------------------------

Study population characteristics (28 patients with AAA and 19 controls) are presented in [Table 1](#jcm-09-01974-t001){ref-type="table"}. Statistically significant differences between AAA and control groups were noticed in relation to age (*p* = 8.30 × 10^−9^), BMI (*p* = 4.05 × 10^−2^), gender (*p* = 2.63 × 10^−3^) and smoking history (*p* = 6.69 × 10^−3^), resulting from inclusion of healthy, AAA-negative individuals in control group ([Table 1](#jcm-09-01974-t001){ref-type="table"}, [Figure S2](#app1-jcm-09-01974){ref-type="app"}).

3.2. Primary Results {#sec3dot2-jcm-09-01974}
--------------------

Results of libraries assessments, Ion Sphere Particles enrichment quality control and results of sequencing data primary analysis are shown in [Tables S1 and S2](#app1-jcm-09-01974){ref-type="app"}. To assess sequencing data quality, MA plot, boxplot of Cook's distances across samples and histogram of *p* values frequency were performed for miRNA ([Figure S3](#app1-jcm-09-01974){ref-type="app"}) and transcriptome ([Figure S4](#app1-jcm-09-01974){ref-type="app"}) sequencing results.

3.3. Differential Expression Analysis of miRNA {#sec3dot3-jcm-09-01974}
----------------------------------------------

Differential expression analysis of miRNA between 28 AAA patients and 19 non-AAA controls was performed using DESeq2 and UVE-PLS methods.

DESeq2 comparative analysis of the miRNA expression signatures revealed 1107 differentially expressed miRNA transcripts in AAA group. Altered expression of 187 miRNA transcripts was characterized by statistical significance (*p* \< 0.05) after adjustment by the Benjamini--Hochberg false discovery rate. To limit false positive results, for further comparison with UVE-PLS results we selected 36 differentially expressed miRNA transcripts (for 32 mature miRNAs) with adjusted *p* \< 0.0001 ([Table S3](#app1-jcm-09-01974){ref-type="app"}).

UVE-PLS analysis has returned 75 informative miRNA transcripts ([Table S4](#app1-jcm-09-01974){ref-type="app"}). The arrangement of prediction error and PLS components as well as cross-validated predictions versus measured values were presented on [Figure S5](#app1-jcm-09-01974){ref-type="app"}.

In the next step, the set of 36 differentially expressed miRNA transcripts (*p* \< 0.0001) identified by DESeq2 method and the set of 75 differentially expressed miRNA transcripts identified by UVE-PLS method as informative were compared on Venn diagram ([Figure 2](#jcm-09-01974-f002){ref-type="fig"}a). The comparison disclosed 33 miRNA transcripts selected by both methods ([Figure 2](#jcm-09-01974-f002){ref-type="fig"}a). Differential expression of these 33 miRNA transcripts is visualized on heat-map with Euclidean clustering and PCA plot ([Figure 2](#jcm-09-01974-f002){ref-type="fig"}b,c, respectively).

Discriminative value of altered expression in selected 33 miRNA transcripts was assessed using ROC analysis. Calculated areas under the curve ranged between 0.981 and 0.795, indicating good ability of AAA classification ([Table 2](#jcm-09-01974-t002){ref-type="table"} and [Table S5](#app1-jcm-09-01974){ref-type="app"}, [Figure S6](#app1-jcm-09-01974){ref-type="app"}). Therefore, a set of 31 mature miRNAs (16 upregulated and 15 downregulated) encoded by selected 33 miRNA transcripts was proposed as the most promising miRNA biomarkers of AAA ([Table 2](#jcm-09-01974-t002){ref-type="table"}).

3.4. Differential Expression Analysis of Genes {#sec3dot4-jcm-09-01974}
----------------------------------------------

Transcriptomic analysis was performed for randomly selected 7 AAA patients and 7 non-AAA controls. Differential expression analysis of genes was performed using DESeq2 and UVE-PLS methods.

DESeq2 analysis revealed 26,816 differentially expressed genes in AAA group when compared to controls. Altered expression of 2238 genes resulted with statistical significance *p* \< 0.05, after adjustment by Benjamini--Hochberg false discovery rate. To limit false positive results, a set of 155 differentially expressed genes with adjusted *p* \< 0.0001 was chosen for further comparison with UVE-PLS results ([Table S6](#app1-jcm-09-01974){ref-type="app"}).

UVE-PLS analysis disclosed 91 informative genes, which expression differentiated AAA and control groups ([Table S7](#app1-jcm-09-01974){ref-type="app"}). [Figure S7](#app1-jcm-09-01974){ref-type="app"} presents the arrangement of prediction error and PLS components and also cross-validated predictions versus measured values.

The comparison between the set of 155 differentially expressed genes revealed by DESeq2 (*p* \< 0.0001) and the set of 91 informative genes selected by UVE-PLS disclosed 51 genes common for both methods ([Figure 3](#jcm-09-01974-f003){ref-type="fig"}a). A potential of these 51 genes to differentiate AAA and control groups was evaluated by PCA analysis and Canberra clustering ([Figure 3](#jcm-09-01974-f003){ref-type="fig"}b,c, respectively).

ROC analysis showed strong discriminative value of changed expression of these 51 genes with an area under the ROC curve varying from 0.939 to 1 ([Table 3](#jcm-09-01974-t003){ref-type="table"} and [Table S8](#app1-jcm-09-01974){ref-type="app"}, [Figure S8](#app1-jcm-09-01974){ref-type="app"}). Therefore, these 51 genes was considered as a panel of transcriptomic biomarkers of AAA ([Table 3](#jcm-09-01974-t003){ref-type="table"}).

Deconvolution procedure revealed estimated proportions of 11 cell subpopulations in PBMCs specimens subjected to transcriptome analysis. The "quanTIseq" method enables to obtain comparisons between cell types and specimens ([Figure S9](#app1-jcm-09-01974){ref-type="app"}) and "MCPcounter" method provides further information in differences between samples ([Figure S10](#app1-jcm-09-01974){ref-type="app"}). Certain differences in proportions of 11 cell subpopulations between samples were noticed; however, further statistics suggests that cell subpopulations composition in PBMCs specimens had no significant influence on the study outcome.

3.5. Correlation Analysis {#sec3dot5-jcm-09-01974}
-------------------------

Demographical characteristics (age, BMI), clinical parameters (maximum aneurysm diameter, thrombus volume and aneurysm neck length) and expression data of 34 selected miRNA transcripts and 51 selected genes of AAA group were included to the correlation analysis ([Table 4](#jcm-09-01974-t004){ref-type="table"}, broaden results are provided in [Table S9 and S10](#app1-jcm-09-01974){ref-type="app"}). Among demographical and clinical characteristics, statistically significant and weak positive correlation was indicated between age and maximum aneurysm diameter (R = 0.42, p = 0.025), as well as between BMI and thrombus volume (R = 0.38, p = 0.045) ([Table S9](#app1-jcm-09-01974){ref-type="app"}). Two upregulated miRNAs: hsa-miR-34a-5p and hsa-miR-574-5p were positively correlated with maximum aneurysm diameter and thrombus volume, respectively, what make them potential targets for AAA prognosis. Hsa-miR-769-5p and hsa-miR-7847-3p are associated with age, pointing them as possible age-associated risk factors of AAA. Statistically significant correlations between genes and age (AC092620.2, PDCD4, SNHG5, SUFU, ZRANB2) as well as BMI (GIT2, RP1-102E24.1, RPL3P9) were also revealed ([Table 4](#jcm-09-01974-t004){ref-type="table"}). Relatively low number of samples does not allow to make categorical conclusions, therefore further studies with larger populations should be performed to confirm these results. To evaluate effects of smoking, coronary artery disease, diabetes mellitus type 2 and hypertension presence in AAA group on miRNA and gene expression, DESeq2 method was applied to find differentially expressed miRNAs and genes in AAA subjects with these conditions in comparison to AAA subjects without them and any of analyzed miRNAs and genes was statistically significantly differentially expressed. This result suggests, that miRNAs and genes identified as potential biomarkers of AAA do not depend on smoking, coronary artery disease, diabetes mellitus type 2 and hypertension; however, this finding should be confirmed in further studies.

3.6. In Silico Identification of miRNA:Gene Interactions {#sec3dot6-jcm-09-01974}
--------------------------------------------------------

Identification of validated and predicted miRNA:gene interactions between 31 miRNAs and 51 genes revealed as potential biomarkers of AAA was processed by multiMiR package. In the analysis, five validated miRNA:gene pairs ([Table S11](#app1-jcm-09-01974){ref-type="app"}) and 60 top 10% predicted miRNA:gene pairs ([Table S12](#app1-jcm-09-01974){ref-type="app"}) were returned. Received interactions were visualized on regulatory network generated using Cytoscape 3.5.1 software ([Figure 4](#jcm-09-01974-f004){ref-type="fig"}).

3.7. Functional Analysis of miRNA Targets {#sec3dot7-jcm-09-01974}
-----------------------------------------

Functional analysis of 18 target genes (*ANKRD13D*, *CPT1A*, *GGT1*, *GIT2*, *HTT*, *KIAA1549L*, *NBEAL2 PDCD4*, *PRDM13*, *SNORA60*, *SNORD94*, *SUFU*, *THOC5*, *UBE4B*, *UPF1*, *ZRANB2*, *ZSWIM8*, and *ZZEF1*) included in the regulatory network was performed using DAVID 6.8 tools and resulted associations are presented in [Table 5](#jcm-09-01974-t005){ref-type="table"}.

Analyzed genes were associated with cardiovascular diseases (*CPT1A*, *THOC5*, *KIAA1549L*), diabetes (*ANKRD13D*, *CPT1A*), lipids metabolism (*CPT1A*, *GIT2*), inflammation mediators (*GGT1*), glutathione metabolism (*GGT1*), aging (*GGT1*, *PDCD4*), cancer (*HTT*, *SUFU*, *UBE4B*, *PDCD4*), RNA transport and processing (*THOC5*, *UPF1*), proteolysis (*SUFU*, *UBE4B*), chemical dependency (*ZZEF1*, *KIAA1549L*)

Seven out of 18 genes are associated with neurological diseases: Alzheimer's disease (*CPT1A*, *SUFU*, *ZSWIM8*, *PDCD4*), schizophrenia (*HTT*, *NBEAL2*) and Parkinson disease (*PRDM13*).

GO enrichment analysis assigned upregulated genes (*ANKRD13D*, *CPT1A*, *GGT1*, *GIT2*, *HTT*, *NBEAL2*, *SUFU*, *THOC5*, *UBE4B*, *UPF1*, *ZSWIM8*, and *ZZEF1*) to positive regulation of cellular catabolic process, mRNA transport and developmental processes, while downregulated genes (*KIAA1549L*, *PDCD4*, *PRDM13*, *SNORA60*, *SNORD94*, and *ZRANB2*) were associated with RNA biosynthesis and gene expression ([Table 5](#jcm-09-01974-t005){ref-type="table"}).

4. Discussion {#sec4-jcm-09-01974}
=============

Searching for precise and robust biomarkers of early AAA is crucial due to very subtle symptoms of the disease and high mortality of ruptured aneurysm. Examining deregulations in miRNA network and consequential effects on gene expression appears as an interesting research tactics for finding novel biomarkers of AAA \[[@B25-jcm-09-01974],[@B26-jcm-09-01974],[@B27-jcm-09-01974]\].

In the presented study, we performed integrated analysis of miRNAome and transcriptome expression in PBMC specimens obtained from patients with AAA and healthy controls. The PBMCs pool is involved in inflammation, an important element of AAA pathology, and therefore, should provide an abundance of information about condition and disorders of vascular system. Moreover, high accessibility of PBMCs facilitates translation of obtained results into clinical practice.

Application of next generation sequencing and multi-stage statistical methodology allowed to select 31 miRNAs ([Table 2](#jcm-09-01974-t002){ref-type="table"}) and 51 genes ([Table 3](#jcm-09-01974-t003){ref-type="table"}) as the most favorable candidates for detection of AAA ([Figure 1](#jcm-09-01974-f001){ref-type="fig"}). Selection of proposed biomarkers was preceded by control of potential false positive results through adopting the higher threshold of statistical significance (*p* \< 0.0001, adjusted by Benjamini--Hochberg false discovery rate) and eliminating uninformative variables using UVE-PLS. High diagnostic value of proposed biomarkers was confirmed in ROC analysis ([Table 2](#jcm-09-01974-t002){ref-type="table"} and [Table 3](#jcm-09-01974-t003){ref-type="table"}, [Tables S5 and S8](#app1-jcm-09-01974){ref-type="app"}, [Figures S6 and S8](#app1-jcm-09-01974){ref-type="app"}). Such stringent criteria applied for biomarkers selection were introduced due to the inability to predict in advance the number of miRNA/genes that should be validated by qPCR, thus allowing us not to design proper experiment accordingly.

There is a limited number of studies regarding miRNA expression investigations by next generation sequencing in PBMC samples in AAA individuals \[[@B26-jcm-09-01974]\]. The comparison of our results and findings obtained in similar studies is presented in [Table 6](#jcm-09-01974-t006){ref-type="table"}. Relatively poor overlap with literature data and our miRNAs list could be explained by differences in methodology applied and biological material subjected to experiments.

In depth discussion regarding functions of DEMs (differentially expressed miRNAs) of this research vastly exceeds capacity of the current paper. [Table A1](#jcm-09-01974-t0A1){ref-type="table"} in [Appendix B](#app3-jcm-09-01974){ref-type="app"} focuses on most important information regarding possible mechanisms of presented miRNAs actions in AAA. The set of revealed miRNAs clearly points to deregulation of numerous signaling pathways like mTOR, PI3K/AKT, TGF-β, NOTCH, MAPK, and NF-κB. Those affect general processes like cell adhesion, proliferation and motility as well as more detailed ones like wound healing and vascular growth. Taken together, this may point to processes engaged in AAA onset and development like vascular wall remodeling, hypoxia, subsequent revascularization and hemorrhage. On the other hand it is worth to draw attention to selected miRNAs, due to their engagement in regulation of genes, occurring in our sequencing data.

Expression levels of miR-21 may vary between types of biological material. In AAA aortic tissue is significantly upregulated \[[@B46-jcm-09-01974]\] whereas in plasma of AAA patients it may be downregulated \[[@B47-jcm-09-01974]\]. We observed exhibited upregulation of miR-21, suggesting that PBMCs may better reflect processes ongoing in affected aortic tissue. Higher levels of miR-21 were observed in low inflammatory state abdominal aneurysms compared to high inflammation phase aneurysm \[[@B48-jcm-09-01974]\]. On the other hand, elevated level of miR-21 in macrophages promote apoptosis and vascular inflammation in atherogenesis \[[@B49-jcm-09-01974]\] and was shown as a biomarker of low extremities arterial disease \[[@B28-jcm-09-01974]\]. Those facts suggests more detailed assessment of miR-21 function in inflammation, atherogenesis and AAA in the future.

Overexpression of miR-21 leads to downregulation of *PDCD4* and *PTEN* inducing cell proliferation, decreasing apoptosis in the aortic wall, alleviating aneurysm expansion and protect against cell injury caused by hydrogen peroxide exposure \[[@B50-jcm-09-01974],[@B51-jcm-09-01974],[@B52-jcm-09-01974]\]. *PDCD4* is involved in atherosclerosis pathology probably through enhancing levels of IL-6 and IL-8 and promoting apoptosis of VSMC in animal models of coronary atherosclerosis \[[@B53-jcm-09-01974]\]. In our study, both upregulation of miR-21-5p and downregulation of *PDCD4* were observed in PBMCs samples of AAA subjects, suggesting pro-inflammatory and antiapoptotic effects in AAA.

We confirmed findings of Lenk et al. \[[@B54-jcm-09-01974]\] demonstrating upregulation of *GGT1* in patients with AAA. This phenomenon was also reported as a signature of low extremities arterial disease (LEAD) \[[@B28-jcm-09-01974]\], suggesting non-specific character of *GGT1* deregulation.

There was no overlap between our findings and gene expression biomarkers of AAA found in some other studies \[[@B55-jcm-09-01974],[@B56-jcm-09-01974],[@B57-jcm-09-01974]\]. The differences in results may stem from dissimilarities in study material, criteria for participants inclusion and methodological approaches.

Integration of miRNA and gene expression analysis enabled identification of miRNA:gene regulatory pairs in AAA, presented on regulatory network ([Figure 4](#jcm-09-01974-f004){ref-type="fig"}). Elevated expression of *UBE4B* may be caused by many miRNAs selected as biomarkers of AAA ([Figure 4](#jcm-09-01974-f004){ref-type="fig"}) and lead to aneurysm expansion through inhibition of endothelial growth factor receptor (EGFR)-mediated proliferation of vascular cells by enhancing EGFR degradation \[[@B58-jcm-09-01974]\]. Upregulation of *ANKRD13D* may affect endocytic trafficking of EGFR by inhibition of its ubiquitinated form from the cell surface, attenuating pro-proliferative signaling of internalized EGFR \[[@B59-jcm-09-01974]\], potentially aggravating AAA. EGFR signaling might be compromised also by upregulation of miR-424-5p, which is a negative regulator of *EGFR* expression, as observed in tumor cells \[[@B60-jcm-09-01974]\]. According to bioinformatic analysis, this miRNA might be a regulator of both *UBE4B* and *ANKRD13D*, affecting also *EGFR* expression \[[@B60-jcm-09-01974]\]. This net of reciprocal regulations may be considered as a part of a mechanism decreasing cell proliferation in AAA through modulation of EGFR signaling.

The preliminary functional analysis of genes regulated by miRNAs revealed terms closely related to vascular pathology, including lipid metabolism, inflammation, atherosclerosis and aging ([Table 5](#jcm-09-01974-t005){ref-type="table"}). Interestingly, there were seven genes associated with neurological disorders, including Alzheimer's disease (*CPT1A*, *SUFU*, *ZSWIM8*, *PDCD4*), schizophrenia (*HTT*, *NBEAL2*) and Parkinson's disease (*PRDM13*). For further comment on neurological relationships of our findings please refer to [Appendix C](#app4-jcm-09-01974){ref-type="app"}.

The highly enriched terms associated with genes regulated by biomarker miRNAs like RNA biosynthesis and transport, positive regulation of catabolic processes and developmental processes suggest more general mechanisms also involved in control of gene expression in AAA.

We are aware of limitations of our study design. It was not established, whether alterations in expression of miRNAs and genes proposed as biomarkers were predictive or responsive to AAA development. Although proposed biomarkers were characterized by high predictive value, supported by high level of statistical significance, multistage selection and ROC confirmation, the clinical application requires confirmation in studies with larger cohorts. PBMCs consists of lymphocytes and monocytes subpopulations, varying in miRNA and gene expression patterns. Nuances in proportions of these subpopulations may affect diagnostic value of indicated biomarkers, thus this effect should be further investigated.

Co-existing diseases may bias evaluation of PBMCs expression profiles on a systemic scale. For this reason many conditions were established as exclusion criteria, as mentioned in experimental section. Such strict evaluation helped us to find expression patterns potentially reflecting the local changes in AAA; however, it entailed statistically significant differences in demographic characteristics between AAA and control groups ([Table 1](#jcm-09-01974-t001){ref-type="table"}). Differences in gender, age and smoking habits might have potentially influenced the study outcome.

The AAA group in our study has men overrepresentation (89.3%, 25 patients) whereas control group is more sex-balanced and include 47% of healthy men (9 subjects) ([Table 1](#jcm-09-01974-t001){ref-type="table"}). Those characteristics may potentially introduce a gender-associated bias into our data. Some of proposed miRNA biomarkers of AAA have already been connected to sex differences in humans ([Table A2](#jcm-09-01974-t0A2){ref-type="table"} in [Appendix D](#app5-jcm-09-01974){ref-type="app"}), suggesting that deregulation of these miRNAs may reflect gender differences occurring between AAA and control group. In the case of gene expression, comparison of Deegan et al. paper \[[@B61-jcm-09-01974]\] draw only five overlapping genes, suggesting minor gender bias, while from \[[@B62-jcm-09-01974]\] there were no such ones ([Table A3](#jcm-09-01974-t0A3){ref-type="table"} in [Appendix E](#app6-jcm-09-01974){ref-type="app"}). Interestingly, Cui et al. discovered that blood is poor material for distinguishing sex associated transcriptome patterns due to relative invariability between genders \[[@B63-jcm-09-01974]\].

The AAA and control groups were age-unmatched (66.39 ± 4.52 years and 36.58 ± 9.97 years, respectively) ([Table 1](#jcm-09-01974-t001){ref-type="table"}). Literature analysis revealed that some of proposed miRNA biomarkers of AAA may also be considered as senescence indicators ([Table A2](#jcm-09-01974-t0A2){ref-type="table"} in [Appendix D](#app5-jcm-09-01974){ref-type="app"}). On the other hand, gene expression in AAA has no or little overlap with senescence/aging biomarkers. One of the proposed AAA biomarkers, *SNORA33*, has been previously associated with normal human aging \[[@B64-jcm-09-01974]\]. In a comprehensive transcriptomic analysis of eight senescence in vitro models \[[@B65-jcm-09-01974]\], 20 out of 51 genes reported in our study were also differentially expressed in senescent cells ([Table A4](#jcm-09-01974-t0A4){ref-type="table"} in [Appendix F](#app7-jcm-09-01974){ref-type="app"}). It could be then possible that senescence characteristics present in our data may be the outcome of general stress(es) due to disease process itself, not only the age.

Smoking is AAA risk factor affecting miRNA expression \[[@B66-jcm-09-01974]\] and in the case of our studies might be another bias-introducing factor, since AAA group includes current smokers (9 persons, 32.1%), while control group is devoid of them ([Table 1](#jcm-09-01974-t001){ref-type="table"}). Only a small number of miRNAs indicated potential bias after comparison with literature ([Table A2](#jcm-09-01974-t0A2){ref-type="table"} in [Appendix D](#app5-jcm-09-01974){ref-type="app"}). Other research regarding signatures of smoking did not provide us with any transcriptomic patterns recurring in our data ([Table A3](#jcm-09-01974-t0A3){ref-type="table"} in [Appendix E](#app6-jcm-09-01974){ref-type="app"}). This suggests an absence of significant smoking-associated bias, probably due to relatively low number of current smokers in AAA group.

Despite of in-depth literature analysis we were unable to exclude unambiguously any miRNAs or gene transcripts from AAA biomarker panels. MiRNAs represent a group of RNAs with pleiotropic regulatory behavior. This does not exclude particular miRNA to act in various cellular processes in different spatiotemporal context. After detailed analysis, we noticed great variability of applied methodologies across literature (refer to literature in [Table A3](#jcm-09-01974-t0A3){ref-type="table"} and [Table A4](#jcm-09-01974-t0A4){ref-type="table"}). It is possible that existing discrepancies may reflect methodological rather than sex/age/smoking bias.

Taking all of this into account, it should be considered that presented data shows either real AAA biomarkers or biomarkers associated with both AAA and AAA predisposing factors.

Due to technical (data storage server capacity) and financial limitations, gene expression analysis was performed for 14 out of 47 study participants. It could be a potential source of bias affecting investigations on miRNA:gene regulatory network; however, we confirmed some previously validated interactions ([Table S11](#app1-jcm-09-01974){ref-type="app"}) and predictive interactions with high probability ([Table S12](#app1-jcm-09-01974){ref-type="app"}). More research with larger populations is needed to confirm our findings and to validate predictive targets.

The results obtained in our study confirm the important role of miRNA in the pathogenesis of AAA, opening a door to deeper understanding of miRNA functions and regulatory network. AAA biomarkers proposed in this research, after further validation in studies with larger and demographically matched cohorts, can be prospectively applied into clinics for differentiation, diagnosis and therapy of AAA.

The research was performed using the equipment purchased within the project "The equipment of innovative laboratories doing research on new medicines used in the therapy of civilization and neoplastic diseases" within the Operational Program Development of Eastern Poland 2007--2013, Priority Axis I Modern Economy, Operations I.3 Innovation Promotion.

The following are available online at <https://www.mdpi.com/2077-0383/9/6/1974/s1>. Figure S1: proportions in white blood cells subpopulations in AAA patients resulted from blood morphology analysis. Figure S2: evaluation of differences between AAA group (n = 28) and the control group (n = 19) for age (A), BMI (B), sex (C) and smoking (D). Statistical significance (*p* values) were calculated using two-sided Mann--Whitney *U* test (for age and BMI) and a two-sided Fisher's exact test (for sex and smoking). Distributions of age and BMI were presented on boxplots (A) and (B), respectively, with whiskers defining region between minimum and maximum values, boxes covering values between 25% and 75% quantile and horizontal lines inside boxes marking median value. Distribution of sex (black---female, gray---male) and smoking (black---no-smokers, grey---smokers) were presented on spine plots (C) and (D), respectively. Figure S3: quality control of data obtained from sequencing of small RNA libraries and results of differential expression analysis performed by DESeq2 package in 28 AAA individuals and 19 healthy controls. (A) Boxplot presents Cook's distances of miRNAs across samples. Whiskers define range between minimum and maximum value of Cook's distance, boxes range between 25% and 75% quartile, horizontal lines inside boxes mark median value. (B) Histogram presenting distribution of DESeq2 *p* values. (C) MA plot showing relation between log2 of fold changes of differentially expressed miRNAs and averages of normalized counts. MiRNAs with *p* value \< 0.1 were marked as red points. Figure S4: quality control of data obtained from sequencing of transcriptome libraries and results of differential expression analysis performed by DESeq2 package between group of 7 AAA individuals and a group of 7 healthy controls. (A) Boxplot presenting Cook's distances of miRNAs across samples. Whiskers define range between minimum and maximum value of Cook's distance, boxes range between 25% and 75% quartile, horizontal lines inside boxes mark median value. (B) Histogram presenting distribution of DESeq2 *p* values. (C) MA plot showing relation between log2 of fold changes of differentially expressed miRNAs and averages of normalized counts. MiRNAs with *p* value \< 0.1 were marked as red points. Figure S5: UVE-PLS differential expression analysis of miRNA expression data of 28 AAA patients compared to 19 healthy controls. Plots present the arrangement of prediction error and PLS components (A) and cross-validated predictions versus measured values (B). Figure S6: results of receiver operating characteristics (ROC) analysis performed for selected 33 miRNA transcripts differentially expressed in AAA. Values of area under curves (AUC) with 95% confidence interval (in brackets) were included in each plot. Figure S7: UVE-PLS differential expression analysis of transcriptomic expression data of 7 AAA individuals compared to 7 healthy controls. Plots present the arrangement of prediction error and PLS components (A) and cross-validated predictions versus measured values (B). Figure S8: results of receiver operating characteristics (ROC) analysis of 51 genes selected as signatures of AAA. Values of area under curves (AUC) with 95% confidence interval (in brackets) were included in each plot. Figure S9: results of deconvolution procedure performed on gene expression datasets of 7 AAA patients and 7 controls using "quanTIseq" method implemented to immunedeconv 2.0.0 package. Figure S10: results of deconvolution procedure performed on gene expression datasets of 7 AAA patients (AAA) and 7 controls (control) using "MCPcounter" method implemented to immunedeconv 2.0.0 package. Two-sided Mann--Whitney test (wilcox.test function in R) was used to calculate statistical significance of differences in score values between AAA and the control group. Table S1: assessment of small RNA samples, small RNA libraries and results of primary analysis of small RNA sequencing data carried out with Ion Torrent small RNA Plugin v5.0.5r3. Table S2: assessment of transcriptome libraries and results of primary analysis of transcriptome sequencing data carried out with Ion Torrent RNASeqAnalysis plugin v.5.0.3.0. Table S3: the set of 36 differentially expressed miRNA transcripts in the group of 28 AAA individuals compared to 19 healthy controls, resulted from DESeq2 analysis with *p* \< 0.0001. MiRNA transcripts were ordered according to increasing *p* value. Table S4: the set of 75 differentially expressed miRNA transcripts in the group of 28 AAA individuals compared to 19 healthy controls, resulted from UVE-PLS analysis. MiRNA transcripts were ordered according to decreasing PLS coefficients. Table S5: results of ROC analysis for 34 miRNA transcripts selected as signatures for AAA. Table S6: results of DESeq2 differential analysis of genes in the group of 7 AAA individuals compared to the group of 7 healthy controls. The table presents 155 differentially expressed genes with *p* \< 0.0001, ordered accordingly to increasing *p* value. Gene names were searched using HUGO multi-symbol checker and gene symbols not assigned to names are termed as "unmatched". Synonyms or previous gene symbols are placed in brackets. Table S7: results of UVE-PLS analysis of miRNA in the group of 7 AAA individuals compared to the group of 7 healthy controls. The table presents 91 differentially expressed genes recognized as informative, ordered according to decreasing PLS coefficients. Gene names were searched using the HUGO Multi-Symbol Checker and gene symbols not assigned to names are termed as "unmatched". Synonyms or previous gene symbols are placed in brackets. Table S8: results of ROC analysis for 51 genes selected as signatures of AAA. Table S9: correlation analysis between maximum aneurysm diameter, thrombus volume, aneurysm neck length, age, BMI and expression of 33 selected miRNA transcripts identified as potential AAA signatures. Table S10: correlation analysis between maximum aneurysm diameter, thrombus volume, aneurysm neck length, age, BMI and expression of 51 selected genes identified as potential AAA signatures. Table S11: experimentally validated miRNA:gene pairs found in silico among 31 miRNAs and 51 genes indicative for AAA. Table S12: top 10% predicted miRNA:gene pairs obtained in silico among 31 miRNAs and 51 genes found as signatures of AAA.

###### 

Click here for additional data file.
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Abdominal Aorta Aneurysm and Control Groups Construction
========================================================

All 28 patients from analyzed abdominal aorta aneurysm (AAA) group were hospitalized in Department of Vascular Surgery of the Independent Public Clinical Hospital No. 1 in Lublin for AAA as the main diagnosis. The lack of comorbidities was a crucial condition to qualify the patient to the study to create as homogenous group as possible. During the recruitment processes, the medical history and comorbidities were analyzed three times by three different physicians: vascular surgeon, anesthetist (two weeks before admission) and then, one more time, at the day of admission by vascular surgeon in order to conclude on current health state before surgery. In this study, we screened 232 AAA patients during first stage of recruitment. A total of 198 patients was excluded due to chronic venous disease (C2-C6 stage), inflammatory aneurysm, false aneurysm, thoracic aorta aneurysm, isolated popliteal or iliac artery aneurysm, aortic and/or arterial dissection, stroke, transient ischemic attack, myocardial infarction, diabetes mellitus type I, symptomatic peripheral arterial disease (ABI \< 0.8), connective tissue disorders including rheumatoid disease, impaired hepatic or renal function, corticoid therapy, infection within previous six weeks, deep venous thrombosis (less than one year), pulmonary embolism, inflammatory and/or infectious disease and cancer. In fact, at the age of 60--70 it is quite impossible to find AAA patients without any kind of comorbidities.

To construct the control group, we aimed to include healthy (confirmed by vascular surgeon) and non-smoking subjects. AAA mainly affects elderly men and often is accompanied with other diseases, what is the reason of presence of differences in age, BMI, gender and smoking between AAA patients and controls. Therefore, it is difficult to find age- and gender-matched control group including healthy subjects and to avoid differences in those features during the study participants' inclusion. We cope with this biological bias by extension of standard statistical methodology by noise reduction using advanced statistical methods (UVE-PLS), and strict significance thresholds (*p* \< 0.0001 for miRNAs and genes). This particular group of subjects was used also in our both previous research as the control group \[[@B28-jcm-09-01974],[@B29-jcm-09-01974]\].

jcm-09-01974-t0A1_Table A1

###### 

Selected most prominent targets and processes affected by differentially expressed miRNAs from presented study, drawn from literature analysis.

  MiRNAs Reported in the Present Study as Upregulated in AAA         
  ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa-miR-21                                                         Function in atherogenesis \[[@B28-jcm-09-01974],[@B46-jcm-09-01974],[@B49-jcm-09-01974]\] and AAA \[[@B48-jcm-09-01974]\], targets *PTEN* \[[@B50-jcm-09-01974],[@B51-jcm-09-01974],[@B52-jcm-09-01974]\].
  hsa-miR-24                                                         Downregulated in plasma of AAA patients and murine AAA models \[[@B67-jcm-09-01974]\].
  hsa-miR-34a                                                        Was deregulated in abdominal aorta tissue of AAA animal models \[[@B67-jcm-09-01974]\].
  hsa-miR-122                                                        Role in Alzheimer's disease through regulation of genes involved in lipid metabolism \[[@B68-jcm-09-01974]\].
  hsa-miR-424                                                        Negative regulator of *EGFR* expression in tumor cells \[[@B60-jcm-09-01974]\], targets Rictor (mTOR complex 2 signaling element), promotes tumor progression \[[@B69-jcm-09-01974]\], affects MAPK and focal adhesion signaling pathways in esophageal squamous cell carcinoma \[[@B70-jcm-09-01974]\].
  hsa-miR-450b                                                       Affects MAPK and focal adhesion signaling pathways in esophageal squamous cell carcinoma \[[@B70-jcm-09-01974]\].
  hsa-miR-454                                                        Directly targets *PTEN* \[[@B71-jcm-09-01974]\], promotes cancer progression \[[@B71-jcm-09-01974],[@B72-jcm-09-01974]\], inhibits Wnt/β-catenin signaling \[[@B72-jcm-09-01974]\].
  hsa-miR-503                                                        Targets Rictor (mTOR complex 2 signaling element), promotes tumor progression \[[@B69-jcm-09-01974]\], promotes ESCC cell proliferation, migration, and invasion by targeting cyclin D1 \[[@B73-jcm-09-01974]\], negative regulator of proliferation in primary human cells \[[@B74-jcm-09-01974]\].
  hsa-miR-542                                                        Upregulated in AAA patients \[[@B42-jcm-09-01974]\].
  hsa-miR-548d                                                       Associated with schizophrenia \[[@B75-jcm-09-01974]\].
  hsa-miR-574                                                        Circulating marker of TAA \[[@B76-jcm-09-01974]\], repressor of *VEGFA* \[[@B77-jcm-09-01974]\], promotes VSMCs growth in CAD \[[@B78-jcm-09-01974]\].
  hsa-miR-3591                                                       Lower extremities arterial disease-associated miRNA \[[@B28-jcm-09-01974]\].
  **MiRNAs reported in the present study as downregulated in AAA**   
  hsa-let-7g                                                         Increases viability of lung cancer and osteosarcoma cells via downregulation of *HOXB1* and activation of NF-kB pathway \[[@B79-jcm-09-01974],[@B80-jcm-09-01974]\].
  hsa-miR-31                                                         Knockdown of this miRNA inhibits expression of Collagen I and III and Fibronectin in hypertrophic scar formation \[[@B81-jcm-09-01974]\], regulator of senescence in cancer cells \[[@B82-jcm-09-01974]\].
  hsa-miR-99a                                                        Significantly decreased in patients with AMI \[[@B83-jcm-09-01974]\], regulates cell migration and cell proliferation by targeting PI3K/AKT and mTOR in wound healing model \[[@B84-jcm-09-01974]\].
  hsa-miR-125b                                                       Associated with immune response of patients with ruptured intracranial aneurysms \[[@B85-jcm-09-01974]\], upregulated in AAA subjects \[[@B44-jcm-09-01974]\], suppresses bladder cancer development by targeting *SIRT7* and *MALAT1* \[[@B86-jcm-09-01974]\].
  hsa-miR-138                                                        Promotes glioma angiogenesis through miR-138/HIF-1α/VEGF axis \[[@B87-jcm-09-01974]\], upregulated after the induction of myocardial infarction \[[@B88-jcm-09-01974]\].
  hsa-miR-150                                                        Inactivates VEGFA/VEGFR2 and the downstream Akt/mTOR signaling pathway in colorectal cancer \[[@B89-jcm-09-01974]\], marker for early diagnosis of AMI \[[@B90-jcm-09-01974]\], underexpression of this miRNA promotes proliferation and metastasis of gastric cancer \[[@B91-jcm-09-01974]\].
  hsa-miR-339                                                        Overexpression of this miRNA can inhibit HCC cell invasion \[[@B92-jcm-09-01974]\].
  hsa-miR-342                                                        Marker of T2D patients with high risk for developing CAD \[[@B93-jcm-09-01974]\], in hUCMSCs enhances osteogenesis by targeting *SUFU*, induces TGF-β expression \[[@B94-jcm-09-01974]\], regulates cell proliferation and apoptosis in hepatocellular carcinoma through Wnt/β-catenin signaling pathway \[[@B95-jcm-09-01974]\].
  hsa-miR-361                                                        Overexpression in cutaneous leishmaniosis lesions, impairs epidermal barrier function by filaggrin-2 repression \[[@B96-jcm-09-01974]\].
  hsa-miR-766                                                        Indirectly inhibits of NF-κB signaling causing anti-inflammatory response \[[@B97-jcm-09-01974]\].
  hsa-miR-769                                                        Expression is significantly correlated with the presence of pronounced coronary atherosclerosis \[[@B98-jcm-09-01974]\], inhibits colorectal cancer cell proliferation and invasion by targeting *HEY1* (downstream effector of NOTCH signaling pathway) \[[@B99-jcm-09-01974]\], negatively correlated with *EGFR* expression \[[@B100-jcm-09-01974]\].
  hsa-miR-874                                                        Decreased expression was associated with poor overall survival of ESCC patients, targets *STAT3* \[[@B101-jcm-09-01974]\].
  hsa-miR-5585                                                       Regulates cell cycle progression in human colorectal carcinoma cells, decreases expression of *TGFβ-R1*, *TGFβ-R2*, *SMAD3*, and *SMAD4* \[[@B102-jcm-09-01974]\].

AAA---aortic abdominal aneurysm, AMI---acute myocardial infraction, CAD---coronary artery disease, EGFR---endothelial growth factor receptor, ESCC---esophagal squamous cells carcinoma, HCC---human colorectal cancer, HEY1---hairy/enhancer-of-split related with YRPW motif protein 1, HIF-1α---hypoxia induced factor 1α, HOXB1---homeobox B1, hUCMSCs---human umbilical cord mesenchymal stem cells, MALAT1---metastasis associated lung adenocarcinoma transcript 1, MAPK---mitogen activated protein kinase, mTOR---mammalian target of rapamycin, NF-κB---necrotic factor κB, NOTCH---translocation-associated protein, PI3K/AKT---phosphoinositide 3-kinases/protein kinase B, PTEN---phosphatase and tensin homolog deleted on chromosome ten, T2D---type 2 diabetes, TAA---thoracic aortic aneurysm, TGF-β---tumor growth factor β, TGFβ-R1---tumor growth factor β receptor 1, TGFβ-R2---tumor growth factor β receptor 2, SIRT7---sirtuin 7, SMAD3---decapentaplegic homolog 3, SMAD4---decapentaplegic homolog 4, STAT3---signal transducer and activator of transcription 3, SUFU---suppressor of fused homolog, Wnt---wingless-type MMTV integration site family of genes, VEGF---vascular endothelial growth factor, VEGFA---vascular endothelial growth factor A, VEGFR2---vascular endothelial growth factor receptor 2, VSMCs---vascular smooth muscle cells.

Neurological Associations of Genes and miRNAs Involved in Abdominal Aortic Aneurysm (AAA) Pathology
===================================================================================================

Although our research was focused on AAA, some additional associations with nervous system diseases were discovered. Interestingly, there were seven genes associated with neurological disorders, like Alzheimer disease (*CPT1A*, *SUFU*, *ZSWIM8*, *PDCD4*), schizophrenia (*HTT*, *NBEAL2*) and Parkinson's disease (*PRDM13*) ([Table 5](#jcm-09-01974-t005){ref-type="table"}). *SUFU* and *PDCD4* genes were linked to Alzheimer's disease and were shown as predictive targets of miR-34a-5p. Upregulation of miR-34a-5p was earlier reported in blood mononuclear cells from individuals with Alzheimer's disease \[[@B103-jcm-09-01974]\]. Both *SUFU* and *PDCD4* were also predictive targets of miR-122-5p involved in development of Alzheimer's disease through regulation of genes involved in lipid metabolism \[[@B68-jcm-09-01974]\]. Another target for miR-34a-5p was *PRDM13*, which was found to be associated with susceptibility to Parkinson's disease. Upregulation of miR-34a was reported in in vitro model of Parkinson's disease \[[@B104-jcm-09-01974]\]. The regulatory network including miR-34a-5p, miR-122-5p, *SUFU*, *PDCD4*, and *PRDM13* may be involved in development of aneurysm-related neurodegenerative diseases. The link between nervous system and cardiovascular diseases is well known and was also confirmed in our earlier research \[[@B28-jcm-09-01974]\].
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Associations of miRNAs proposed in our study as abdominal aortic aneurysm (AAA) biomarkers with gender and aging, found in the most relevant literature.

  ------------------------------------------------------------------ --------------------------------------------------- -------------------------------------------------- ----------------------------------------------------
  **miRNAs**                                                         Previous studies reported association with gender   Previous studies reported association with aging   Previous studies reported association with smoking
  **miRNAs reported in the present study as upregulated in AAA**                                                                                                            
  hsa-miR-21                                                         \[[@B105-jcm-09-01974]\]                            \[[@B106-jcm-09-01974]\]                           
  hsa-miR-24                                                                                                             \[[@B106-jcm-09-01974],[@B107-jcm-09-01974]\]      
  hsa-miR-34a                                                                                                            \[[@B108-jcm-09-01974]\]                           
  hsa-miR-122                                                                                                            \[[@B106-jcm-09-01974]\]                           
  hsa-miR-424                                                        \[[@B63-jcm-09-01974],[@B105-jcm-09-01974]\]        \[[@B106-jcm-09-01974]\]                           
  hsa-miR-450b                                                                                                                                                              
  hsa-miR-454                                                        \[[@B63-jcm-09-01974]\]                                                                                
  hsa-miR-503                                                                                                            \[[@B106-jcm-09-01974]\]                           
  hsa-miR-542                                                                                                                                                               
  hsa-miR-548d                                                                                                           \[[@B106-jcm-09-01974]\]                           
  hsa-miR-574                                                                                                                                                               \[[@B109-jcm-09-01974]\]
  hsa-miR-3591                                                                                                                                                              
  **miRNAs reported in the present study as downregulated in AAA**                                                                                                          
  hsa-let-7g                                                                                                             \[[@B106-jcm-09-01974],[@B107-jcm-09-01974]\]      
  hsa-miR-31                                                                                                                                                                
  hsa-miR-99a                                                        \[[@B63-jcm-09-01974]\]                             \[[@B110-jcm-09-01974]\]                           
  hsa-miR-125b                                                                                                           \[[@B106-jcm-09-01974]\]                           
  hsa-miR-138                                                                                                            \[[@B106-jcm-09-01974],[@B107-jcm-09-01974]\]      \[[@B111-jcm-09-01974]\]
  hsa-miR-150                                                        \[[@B63-jcm-09-01974],[@B105-jcm-09-01974]\]                                                           
  hsa-miR-339                                                        \[[@B63-jcm-09-01974]\]                                                                                
  hsa-miR-342                                                        \[[@B105-jcm-09-01974]\]                                                                               
  hsa-miR-361                                                        \[[@B63-jcm-09-01974]\]                                                                                
  hsa-miR-766                                                                                                            \[[@B106-jcm-09-01974]\]                           \[[@B112-jcm-09-01974]\]
  hsa-miR-769                                                        \[[@B63-jcm-09-01974]\]                                                                                
  hsa-miR-874                                                                                                            \[[@B106-jcm-09-01974]\]                           
  hsa-miR-5585                                                                                                                                                              
  ------------------------------------------------------------------ --------------------------------------------------- -------------------------------------------------- ----------------------------------------------------
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###### 

Associations of genes proposed in our study as AAA biomarkers with gender and smoking, found in the most relevant literature.

  No.                       Gene Symbol             Association with Gender   Association with Smoking                                      
  ------------------------- ----------------------- ------------------------- -------------------------- ---- ---- ---- ---- ---- ---- ---- ----
  1                         *CPT1A*                 no                        no                         no   no   no   no   no   no   no   no
  2                         *GGT1*                  no                        no                         no   no   no   no   no   no   no   no
  3                         *UPF1*                  yes, f                    no                         no   no   no   no   no   no   no   no
  4                         *AC092620.2*            no                        no                         no   no   no   no   no   no   no   no
  5                         *UBE4B*                 yes, f                    no                         no   no   no   no   no   no   no   no
  6                         *HTT*                   no                        no                         no   no   no   no   no   no   no   no
  7                         *NBEAL2*                no                        no                         no   no   no   no   no   no   no   no
  8                         *GIT2*                  no                        no                         no   no   no   no   no   no   no   no
  9                         *THOC5*                 no                        no                         no   no   no   no   no   no   no   no
  10                        *ZZEF1*                 no                        no                         no   no   no   no   no   no   no   no
  11                        *ANKRD13D*              no                        no                         no   no   no   no   no   no   no   no
  12                        *SUFU*                  no                        no                         no   no   no   no   no   no   no   no
  13                        *RN7SKP89*              no                        no                         no   no   no   no   no   no   no   no
  14                        *ZSWIM8*                no                        no                         no   no   no   no   no   no   no   no
  **Downregulated genes**                                                                                                                   
  15                        *SNORA60*               no                        no                         no   no   no   no   no   no   no   no
  16                        *MIRLET7F2*             no                        no                         no   no   no   no   no   no   no   no
  17                        *SNHG5*                 no                        no                         no   no   no   no   no   no   no   no
  18                        *SNORD20*               no                        no                         no   no   no   no   no   no   no   no
  19                        *SNORA72*               no                        no                         no   no   no   no   no   no   no   no
  20                        *SNORD117*              no                        no                         no   no   no   no   no   no   no   no
  21                        *SNORD82*               yes, m                    no                         no   no   no   no   no   no   no   no
  22                        *SNORD94*               no                        no                         no   no   no   no   no   no   no   no
  23                        *SNORD101*              no                        no                         no   no   no   no   no   no   no   no
  24                        *RNA5SP355*             no                        no                         no   no   no   no   no   no   no   no
  25                        *SNORD103C (SNORD85)*   no                        no                         no   no   no   no   no   no   no   no
  26                        *RPL3P9*                no                        no                         no   no   no   no   no   no   no   no
  27                        *RP11-16F15.2*          no                        no                         no   no   no   no   no   no   no   no
  28                        *RP11-302F12.1*         no                        no                         no   no   no   no   no   no   no   no
  29                        *SNORA12*               no                        no                         no   no   no   no   no   no   no   no
  30                        *SNORA33*               no                        no                         no   no   no   no   no   no   no   no
  31                        *ZRANB2*                yes, m                    no                         no   no   no   no   no   no   no   no
  32                        *SNORD91B*              no                        no                         no   no   no   no   no   no   no   no
  33                        *RP11-253E3.1*          no                        no                         no   no   no   no   no   no   no   no
  34                        *SNORD103B*             no                        no                         no   no   no   no   no   no   no   no
  35                        *SNORD127*              no                        no                         no   no   no   no   no   no   no   no
  36                        *SNORD103A*             no                        no                         no   no   no   no   no   no   no   no
  37                        *SCARNA13*              no                        no                         no   no   no   no   no   no   no   no
  38                        *SNORA14B*              no                        no                         no   no   no   no   no   no   no   no
  39                        *KIAA1549L*             no                        no                         no   no   no   no   no   no   no   no
  40                        *SNORD119*              no                        no                         no   no   no   no   no   no   no   no
  41                        *PDCD4*                 yes, m                    no                         no   no   no   no   no   no   no   no
  42                        *MIR181A1*              no                        no                         no   no   no   no   no   no   no   no
  43                        *SCARNA9*               no                        no                         no   no   no   no   no   no   no   no
  44                        *RP1-102E24.1*          no                        no                         no   no   no   no   no   no   no   no
  45                        *PRDM13*                no                        no                         no   no   no   no   no   no   no   no
  46                        *SNORD19*               no                        no                         no   no   no   no   no   no   no   no
  47                        *SNORA26*               no                        no                         no   no   no   no   no   no   no   no
  48                        *RNU2-36P*              no                        no                         no   no   no   no   no   no   no   no
  49                        *SNORA50A (SNORA50)*    no                        no                         no   no   no   no   no   no   no   no
  50                        *SNORA40*               no                        no                         no   no   no   no   no   no   no   no
  51                        *SNORD1B*               no                        no                         no   no   no   no   no   no   no   no

^1^ Heart tissue gender bias only, ^2^ xenobiotic metabolism genes only, ^3^ CpG island methylation only, full data comparison, ^4^ genes associated with smoking behavior, ^5^ full data comparison, f---female biased, m---male biased, no---there is no association between presented data and literature, yes---there is an association between presented data and literature.
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Associations of genes proposed in our study as AAA biomarkers with aging, found in the most relevant literature.

  No.                       Gene Symbol             Associations with Aging:                         
  ------------------------- ----------------------- -------------------------- ---- ----- ---- ----- -----------------------------------------------------------
  1                         *CPT1A*                 no                         no   no    no   yes   IMR90 IR, IMR90 Rep, HUVEC IR, HAEC IR, WI38 Onc
  2                         *GGT1*                  no                         no   no    no   yes   WI38 IR, WI38 Onc, WI38 Dox, IMR90 IR, WI38 Rep, HUVEC IR
  3                         *UPF1*                  no                         no   no    no   yes   IMR90 Rep, IMR90 IR, WI38 Onc,
  4                         *AC092620.2*            no                         no   no    no   yes   WI38 Onc
  5                         *UBE4B*                 no                         no   no    no   yes   IMR90 Rep, IMR90 IR
  6                         *HTT*                   no                         no   no    no   yes   IMR90 Rep, WI38 Onc, IMR90 IR
  7                         *NBEAL2*                no                         no   no    no   yes   WI38 Onc, HAEC IR, WI38 Dox
  8                         *GIT2*                  no                         no   no    no   yes   IMR90 Rep, WI38 Dox, IMR90 IR, WI38 Onc
  9                         *THOC5*                 no                         no   no    no   no    
  10                        *ZZEF1*                 no                         no   no    no   no    
  11                        *ANKRD13D*              no                         no   no    no   no    
  12                        *SUFU*                  no                         no   no    no   yes   HUVEC IR
  13                        *RN7SKP89*              no                         no   no    no   no    
  14                        *ZSWIM8*                no                         no   no    no   yes   HUVEC IR, IMR90 IR, IMR90 Rep
  **Downregulated genes**                                                                            
  15                        *SNORA60*               no                         no   no    no   no    
  16                        *MIRLET7F2*             no                         no   no    no   no    
  17                        *SNHG5*                 no                         no   no    no   yes   HUVEC IR
  18                        *SNORD20*               no                         no   no    no   no    
  19                        *SNORA72*               no                         no   no    no   no    
  20                        *SNORD117*              no                         no   no    no   no    
  21                        *SNORD82*               no                         no   no    no   no    
  22                        *SNORD94*               no                         no   no    no   yes   WI38 Dox
  23                        *SNORD101*              no                         no   no    no   yes   HAEC IR, WI38 Dox, WI38 Onc, HUVEC IR
  24                        *RNA5SP355*             no                         no   no    no   no    
  25                        *SNORD103C (SNORD85)*   no                         no   no    no   no    
  26                        *RPL3P9*                no                         no   no    no   no    
  27                        *RP11-16F15.2*          no                         no   no    no   yes   WI38 Rep
  28                        *RP11-302F12.1*         no                         no   no    no   no    
  29                        *SNORA12*               no                         no   no    no   no    
  30                        *SNORA33*               no                         no   yes   no   no    
  31                        *ZRANB2*                no                         no   no    no   no    
  32                        *SNORD91B*              no                         no   no    no   no    
  33                        *RP11-253E3.1*          no                         no   no    no   no    
  34                        *SNORD103B*             no                         no   no    no   no    
  35                        *SNORD127*              no                         no   no    no   no    
  36                        *SNORD103A*             no                         no   no    no   no    
  37                        *SCARNA13*              no                         no   no    no   no    
  38                        *SNORA14B*              no                         no   no    no   yes   WI38 Dox, WI38 Onc
  39                        *KIAA1549L*             no                         no   no    no   yes   WI38 Dox, IMR90 Rep, IMR90 IR, WI38 IR, WI38 Onc
  40                        *SNORD119*              no                         no   no    no   no    
  41                        *PDCD4*                 no                         no   no    no   yes   WI38 Onc, HUVEC IR, HAEC IR, WI38 Dox, WI38 Rep
  42                        *MIR181A1*              no                         no   no    no   no    
  43                        *SCARNA9*               no                         no   no    no   yes   WI38 Onc, HUVEC IR, IMR90 Rep, IMR90 IR
  44                        *RP1-102E24.1*          no                         no   no    no   no    
  45                        *PRDM13*                no                         no   no    no   no    
  46                        *SNORD19*               no                         no   no    no   yes   WI38 Dox, WI38 Onc, HUVEC IR
  47                        *SNORA26*               no                         no   no    no   yes   WI38 Dox, IMR90 Rep
  48                        *RNU2-36P*              no                         no   no    no   no    
  49                        *SNORA50A (SNORA50)*    no                         no   no    no   no    
  50                        *SNORA40*               no                         no   no    no   no    
  51                        *SNORD1B*               no                         no   no    no   no    

^1^ Genes with *p* \< 0.0001 were analyzed, HAEC---human aortic endothelial cells, HUVEC---human umbilical vein endothelial cells, Dox---doxorubicin-induced senescence, IMR90---human diploid fibroblasts from fetal lung, IR---irradiation induced senescence, Rep---replicative exhaustion induced senescence, Onc---oncogene induced senescence, WI38---human diploid fibroblasts from fetal lung, no---there is no association between presented data and literature, yes---there is an association between presented data and literature

![The scheme summarizing applied methodology and general results. AAA---abdominal aortic aneurysm.](jcm-09-01974-g001){#jcm-09-01974-f001}

![Differential expression analysis of miRNA in PBMCs samples derived from 28 patients with abdominal aortic aneurysm (AAA) and 19 controls (control). (**a**) Venn diagram presenting comparison of two sets of miRNA transcripts: set of 36 miRNA transcripts indicated by DESeq2 analysis with *p* \< 0.0001 and set of 75 miRNA transcripts indicated by uninformative variable elimination by partial least squares (UVE-PLS) analysis as informative. A total of 33 miRNA transcripts were common for both analyzed sets. Principal component analysis (PCA) plot (**b**) and heat-map with Euclidean clustering (complete linkage) (**c**) of these common 33 miRNA transcripts.](jcm-09-01974-g002){#jcm-09-01974-f002}

![Differential expression analysis of genes in abdominal aortic aneurysm group (AAA) and controls group (control). (**a**) Set of 155 genes indicated by DESeq2 analysis with *p* \< 0.0001 and set of 91 genes indicated by uninformative variable elimination by partial least squares (UVE-PLS) analysis were compared on Venn diagram showing 51 common genes. Principal component analysis (PCA) plot (**b**) and heat-map with Canberra clustering (**c**) for expression of common 51 genes.](jcm-09-01974-g003){#jcm-09-01974-f003}

![Regulatory network presenting interactions between miRNAs and genes proposed as indicative for abdominal aortic aneurysm.](jcm-09-01974-g004){#jcm-09-01974-f004}
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###### 

Characteristics of 28 patients with abdominal aortic aneurysm (AAA) and 19 controls included to the study.

  ---------------------------------------------------------------------------------------------------------------------------
  Characteristic                                      AAA Population (n = 28)   Control Population (n = 19)   *p*
  --------------------------------------------------- ------------------------- ----------------------------- ---------------
  Age                                                 66.39 ± 4.52 ^1^\         36.58 ± 9.97 ^1^\             8.30 × 10^−9^
                                                      57--76 ^2^                24--55 ^2^                    

  Body Mass Index                                     25.08 ± 3.30 ^1^\         23.12 ± 3.93 ^1^\             4.05 × 10^−2^
                                                      18.03--31.25 ^2^          19.33--32.6 ^2^               

  Current smoking                                     9 (32.1%)                 0 (0%)                        6.69 × 10^−3^

  Sex: Male                                           25 (89.3%)                9 (47%)                       2.63 × 10^−3^

  Sex: Female                                         3 (10.7%)                 10 (53%)                      

  **Abdominal aneurysm measurements**                                                                         

  Maximum aneurysm diameter (cm)                      6.389 ± 0.633 ^1^\        NA                            
                                                      5.6--7.8 ^2^                                            

  Thrombus volume (cm^3^)                             9.782 ± 3.296 ^1^\        NA                            
                                                      2.9--16.5 ^2^                                           

  Aneurysm neck length (cm)                           0.925 ± 0.219 ^1^\        NA                            
                                                      0.5--1.3 ^2^                                            

  **Risk factors and cardiovascular comorbidities**                                                           

  Coronary artery disease                             7 (25.0%)                 NA                            

  Diabetes type 2                                     6 (21.4%)                 NA                            

  Hypertension                                        19 (67.9%)                NA                            

  **Clinical parameters**                                                                                     

  Red blood cells (M/µL)                              4.94 ± 0.21 ^1^\          NA                            
                                                      4.56--5.50 ^2^                                          

  White blood cells (K/µL)                            5.66 ± 0.70 ^1^\          NA                            
                                                      4.44--6.90 ^2^                                          

  Platelets (K/µL)                                    419.93 ± 123.98 ^1^\      NA                            
                                                      211 -- 756 ^2^                                          

  Hemoglobin (g/dL)                                   14.02 ± 0.51 ^1^\         NA                            
                                                      13.34--15.00 ^2^                                        

  Hematocrit (%)                                      40.75 ± 1.30 ^1^\         NA                            
                                                      38--43 ^2^                                              

  Creatinine (mmol/L)                                 54.18 ±11.53 ^1^\         NA                            
                                                      39--87 ^2^                                              

  Urea (mmol/L)                                       4.66 ± 0.67 ^1^\          NA                            
                                                      3.45--5.88 ^2^                                          

  **Medication**                                                                                              

  Statins                                             13 (46.4%)                NA                            

  Acetylsalicylic acid                                27 (96.4%)                NA                            

  Clopidogrel                                         3 (10.7%)                 NA                            

  Beta-adrenergic blockers                            16 (57.1%)                NA                            

  Angiotensin Converting Enzyme Inhibitor             4 (14.3%)                 NA                            

  Ca^2+^ channel blockers                             2 (7.14%)                 NA                            

  Fibrates                                            2 (7.14%)                 NA                            

  Metformin                                           3 (10.7%)                 NA                            

  Gliclazide                                          4 (14.3%)                 NA                            

  **Treatment**                                                                                               

  Open surgery                                        2 (7.14%)                 NA                            

  Stent graft                                         26 (92.9%)                NA                            
  ---------------------------------------------------------------------------------------------------------------------------

^1^ Mean ± SD, ^2^ range. Statistical significance (*p*) of differences between AAA and control group in age and body mass index were determined using two-sided Mann--Whitney *U* test, and in sex and smoking habits were determined using two-sided Fisher's exact test. AAA---Abdominal Aortic Aneurysm, "NA"---not applicable.
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###### 

Set of 33 miRNA transcripts, which significance of differential expression was confirmed by DESeq2 analysis with *p* \< 0.0001 and by uninformative variable elimination by partial least squares (UVE-PLS) analysis in patients with abdominal aortic aneurysm in comparison to controls.

  No.                                   miRNA Transcript                 miRNA ID^\*^      *p*              Fold Change   PLS Coefficient   ROC-AUC
  ------------------------------------- -------------------------------- ----------------- ---------------- ------------- ----------------- ---------
  1                                     hsa-mir-21_hsa-miR-21-5p         hsa-miR-21-5p     9.19 × 10^−12^   1.356         1.61 × 10^−2^     0.953
  2                                     hsa-mir-21_hsa-miR-21-3p         hsa-miR-21-3p     1.73 × 10^−9^    1.704         2.77 × 10^−2^     0.919
  3                                     hsa-mir-34a_hsa-miR-34a-5p       hsa-miR-34a-5p    5.61 × 10^−9^    2.188         4.04 × 10^−2^     0.927
  4                                     hsa-mir-454_hsa-miR-454-3p       hsa-miR-454-3p    2.74 × 10^−8^    1.216         1.15 × 10^−2^     0.940
  5                                     hsa-mir-574_hsa-miR-574-5p       hsa-miR-574-5p    1.13 × 10^−6^    1.364         1.65 × 10^−2^     0.898
  6                                     hsa-mir-424_hsa-miR-424-3p       hsa-miR-424-3p    2.03 × 10^−6^    1.872         2.61 × 10^−2^     0.861
  7                                     hsa-mir-450b_hsa-miR-450b-5p     hsa-miR-450b-5p   2.76 × 10^−6^    1.834         2.54 × 10^−2^     0.872
  8                                     hsa-mir-24-2_hsa-miR-24-3p       hsa-miR-24-3p     8.59 × 10^−6^    1.143         6.77 × 10^−3^     0.874
  9                                     hsa-mir-34a_hsa-miR-34a-3p       hsa-miR-34a-3p    1.42 × 10^−5^    2.357         2.42 × 10^−2^     0.867
  10                                    hsa-mir-542_hsa-miR-542-3p       hsa-miR-542-3p    4.14 × 10^−5^    1.666         1.86 × 10^−2^     0.852
  11                                    hsa-mir-503_hsa-miR-503-5p       hsa-miR-503-5p    6.92 × 10^−5^    1.781         1.99 × 10^−2^     0.821
  12                                    hsa-mir-7847_hsa-miR-7847-3p     hsa-miR-7847-3p   7.00 × 10^−5^    2.270         2.45 × 10^−2^     0.861
  13                                    hsa-mir-548d-1_hsa-miR-548d-3p   hsa-miR-548d-3p   7.10 × 10^−5^    1.493         9.31 × 10^−3^     0.848
  14                                    hsa-mir-122_hsa-miR-122-5p       hsa-miR-122-5p    7.94 × 10^−5^    1.790         1.88 × 10^−2^     0.795
  15                                    hsa-mir-3591_hsa-miR-3591-3p     hsa-miR-3591-3p   7.94 × 10^−5^    1.789         1.88 × 10^−2^     0.795
  16                                    hsa-mir-424_hsa-miR-424-5p       hsa-miR-424-5p    9.56 × 10^−5^    1.579         1.79 × 10^−2^     0.810
  **Downregulated miRNA transcripts**                                                                                                       
  17                                    hsa-mir-31_hsa-miR-31-5p         hsa-miR-31-5p     4.18 × 10^−12^   0.344         −4.97 × 10^−2^    0.981
  18                                    hsa-mir-31_hsa-miR-31-3p         hsa-miR-31-3p     4.18 × 10^−12^   0.329         −5.27 × 10^−2^    0.970
  19                                    hsa-mir-874_hsa-miR-874-5p       hsa-miR-874-5p    7.39 × 10^−11^   0.429         −3.33 × 10^−2^    0.934
  20                                    hsa-mir-361_hsa-miR-361-3p       hsa-miR-361-3p    8.26 × 10^−10^   0.683         −1.81 × 10^−2^    0.945
  21                                    hsa-mir-342_hsa-miR-342-3p       hsa-miR-342-3p    1.22 × 10^−7^    0.592         −1.94 × 10^−2^    0.923
  22                                    hsa-mir-138-1_hsa-miR-138-5p     hsa-miR-138-5p    3.65 × 10^−7^    0.368         −4.28 × 10^−2^    0.852
  23                                    hsa-mir-125b-2_hsa-miR-125b-5p   hsa-miR-125b-5p   1.32 × 10^−6^    0.552         −2.56 × 10^−2^    0.868
  24                                    hsa-mir-150_hsa-miR-150-5p       hsa-miR-150-5p    1.88 × 10^−6^    0.581         −2.04 × 10^−2^    0.906
  25                                    hsa-mir-3607_hsa-miR-3607-5p     hsa-miR-3607-5p   2.03 × 10^−6^    0.532         −2.86 × 10^−2^    0.880
  26                                    hsa-mir-769_hsa-miR-769-5p       hsa-miR-769-5p    5.36 × 10^−6^    0.813         −9.44 × 10^−3^    0.874
  27                                    hsa-let-7g_hsa-let-7g-3p         hsa-let-7g-3p     7.34 × 10^−6^    0.750         −1.16 × 10^−2^    0.887
  28                                    hsa-mir-125b-1_hsa-miR-125b-5p   hsa-miR-125b-5p   7.34 × 10^−6^    0.560         −2.35 × 10^−2^    0.857
  29                                    hsa-mir-138-2_hsa-miR-138-5p     hsa-miR-138-5p    2.47 × 10^−5^    0.397         −3.78 × 10^−2^    0.863
  30                                    hsa-mir-339_hsa-miR-339-3p       hsa-miR-339-3p    4.31 × 10^−5^    0.770         −1.00 × 10^−2^    0.868
  31                                    hsa-mir-5585_hsa-miR-5585-3p     hsa-miR-5585-3p   4.64 × 10^−5^    0.396         −1.91 × 10^−2^    0.801
  32                                    hsa-mir-99a_hsa-miR-99a-3p       hsa-miR-99a-3p    6.92 × 10^−5^    0.481         −2.38 × 10^−2^    0.853
  33                                    hsa-mir-766_hsa-miR-766-3p       hsa-miR-766-3p    8.72 × 10^−5^    0.808         −1.63 × 10^−2^    0.852

^1^ According to miRBase 22 (<http://www.mirbase.org/>). Presented 33 miRNA transcripts give 31 mature miRNAs (miRNA IDs). The table presents *p* (after Benjamini--Hochberg false discovery rate correction) and fold change values resulted from DESeq2 analysis, PLS (partial least squares) coefficients resulted from UVE-PLS (uninformative variable elimination by partial least squares) analysis and areas under ROC (receiver operating characteristics) curves (ROC-area under curves (AUC)) resulted from ROC analysis. MiRNA transcripts were divided into upregulated and downregulated groups and ordered according to increasing *p* value.
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###### 

Set of 51 differentially expressed genes, which significance of differential expression was confirmed by DESeq2 analysis with *p* \< 0.0001 and by uninformative variable elimination by partial least squares (UVE-PLS) analysis in patients with abdominal aortic aneurysm in comparison to controls.

  No.                       Gene Symbol             Gene Name                                             *P*              Fold Change   PLS Coefficient   ROC-AUC
  ------------------------- ----------------------- ----------------------------------------------------- ---------------- ------------- ----------------- ---------
  1                         *CPT1A*                 carnitine palmitoyltransferase 1A                     1.70 × 10^−10^   2.487         1.567 × 10^−3^    1.000
  2                         *GGT1*                  gamma-glutamyltransferase 1                           1.11 × 10^−8^    1.973         9.424 × 10^−4^    1.000
  3                         *UPF1*                  UPF1 RNA helicase and ATPase                          2.43 × 10^−8^    1.321         4.369 × 10^−4^    1.000
  4                         *AC092620.2*            Unmatched                                             8.85 × 10^−7^    2.867         1.239 × 10^−3^    1.000
  5                         *UBE4B*                 ubiquitination factor E4B                             5.72 × 10^−6^    1.300         3.839 × 10^−4^    1.000
  6                         *HTT*                   huntingtin                                            1.12 × 10^−5^    1.388         4.526 × 10^−4^    1.000
  7                         *NBEAL2*                neurobeachin like 2                                   1.38 × 10^−5^    1.517         5.590 × 10^−4^    1.000
  8                         *GIT2*                  GIT ArfGAP 2                                          2.08 × 10^−5^    1.449         5.331 × 10^−4^    1.000
  9                         *THOC5*                 THO complex 5                                         2.72 × 10^−5^    1.319         4.027 × 10^−4^    1.000
  10                        *ZZEF1*                 zinc finger ZZ-type and EF-hand domain containing 1   2.82 × 10^−5^    1.291         3.325 × 10^−4^    1.000
  11                        *ANKRD13D*              ankyrin repeat domain 13D                             3.01 × 10^−5^    1.428         4.791 × 10^−4^    1.000
  12                        *SUFU*                  SUFU negative regulator of hedgehog signaling         4.11 × 10^−5^    1.482         5.397 × 10^−4^    1.000
  13                        *RN7SKP89*              RN7SK pseudogene 89                                   4.45 × 10^−5^    2.764         8.740 × 10^−4^    0.980
  14                        *ZSWIM8*                zinc finger SWIM-type containing 8                    5.52 × 10^−5^    1.355         4.127 × 10^−4^    1.000
  **Downregulated genes**                                                                                                                                  
  15                        *SNORA60*               small nucleolar RNA, H/ACA box 60                     1.19 × 10^−11^   0.547         −1.082 × 10^−3^   1.000
  16                        *MIRLET7F2*             microRNA let-7f-2                                     4.89 × 10^−10^   0.285         −1.620 × 10^−3^   1.000
  17                        *SNHG5*                 small nucleolar RNA host gene 5                       5.05 × 10^−10^   0.433         −1.296 × 10^−3^   1.000
  18                        *SNORD20*               small nucleolar RNA, C/D box 20                       7.75 × 10^−10^   0.235         −2.069 × 10^−3^   1.000
  19                        *SNORA72*               small nucleolar RNA, H/ACA box 72                     3.72 × 10^−9^    0.358         −1.464 × 10^−3^   1.000
  20                        *SNORD117*              small nucleolar RNA, C/D box 117                      1.11 × 10^−8^    0.457         −1.228 × 10^−3^   1.000
  21                        *SNORD82*               small nucleolar RNA, C/D box 82                       1.17 × 10^−8^    0.357         −1.448 × 10^−3^   1.000
  22                        *SNORD94*               small nucleolar RNA, C/D box 94                       5.10 × 10^−8^    0.387         −1.642 × 10^−3^   1.000
  23                        *SNORD101*              small nucleolar RNA, C/D box 101                      5.43 × 10^−8^    0.330         −1.558 × 10^−3^   1.000
  24                        *RNA5SP355*             RNA, 5S ribosomal pseudogene 355                      8.24 × 10^−8^    0.053         −1.178 × 10^−3^   1.000
  25                        *SNORD103C (SNORD85)*   small nucleolar RNA, C/D box 103C                     1.34 × 10^−7^    0.342         −1.352 × 10^−3^   0.980
  26                        *RPL3P9*                ribosomal protein L3 pseudogene 9                     1.87 × 10^−7^    0.260         −1.237 × 10^−3^   0.980
  27                        *RP11-16F15.2*          Unmatched                                             2.06 × 10^−7^    0.344         −1.054 × 10^−3^   1.000
  28                        *RP11-302F12.1*         Unmatched                                             2.25 × 10^−7^    0.194         −1.588 × 10^−3^   1.000
  29                        *SNORA12*               small nucleolar RNA, H/ACA box 12                     4.92 × 10^−7^    0.631         −7.161 × 10^−4^   1.000
  30                        *SNORA33*               small nucleolar RNA, H/ACA box 33                     6.82 × 10^−7^    0.633         −7.151 × 10^−4^   1.000
  31                        *ZRANB2*                zinc finger RANBP2-type containing 2                  7.81 × 10^−7^    0.710         −5.094 × 10^−4^   1.000
  32                        *SNORD91B*              small nucleolar RNA, C/D box 91B                      9.72 × 10^−7^    0.324         −1.497 × 10^−3^   1.000
  33                        *RP11-253E3.1*          Unmatched                                             1.32 × 10^−6^    0.315         −1.007 × 10^−3^   1.000
  34                        *SNORD103B*             small nucleolar RNA, C/D box 103B                     2.34 × 10^−6^    0.338         −1.417 × 10^−3^   1.000
  35                        *SNORD127*              small nucleolar RNA, C/D box 127                      3.36 × 10^−6^    0.511         −1.002 × 10^−3^   1.000
  36                        *SNORD103A*             small nucleolar RNA, C/D box 103A                     4.06 × 10^−6^    0.354         −1.379 × 10^−3^   1.000
  37                        *SCARNA13*              small Cajal body-specific RNA 13                      4.13 × 10^−6^    0.689         −4.895 × 10^−4^   1.000
  38                        *SNORA14B*              small nucleolar RNA, H/ACA box 14B                    4.66 × 10^−6^    0.592         −7.310 × 10^−4^   1.000
  39                        *KIAA1549L*             KIAA1549 like                                         5.44 × 10^−6^    0.178         −1.223 × 10^−3^   0.980
  40                        *SNORD119*              small nucleolar RNA, C/D box 119                      5.58 × 10^−6^    0.427         −1.048 × 10^−3^   1.000
  41                        *PDCD4*                 programmed cell death 4                               9.40 × 10^−6^    0.654         −5.442 × 10^−4^   1.000
  42                        *MIR181A1*              microRNA 181a-1                                       9.42 × 10^−6^    0.112         −1.680 × 10^−3^   0.980
  43                        *SCARNA9*               small Cajal body-specific RNA 9                       1.14 × 10^−5^    0.539         −8.278 × 10^−4^   1.000
  44                        *RP1-102E24.1*          Unmatched                                             1.19 × 10^−5^    0.315         -1.006 × 10^−3^   0.939
  45                        *PRDM13*                PR/SET domain 13                                      2.46 × 10^−5^    0.140         −1.674 × 10^−3^   0.959
  46                        *SNORD19*               small nucleolar RNA, C/D box 19                       3.45 × 10^−5^    0.541         −7.859 × 10^−4^   1.000
  47                        *SNORA26*               small nucleolar RNA, H/ACA box 26                     3.67 × 10^−5^    0.425         −1.156 × 10^−3^   1.000
  48                        *RNU2-36P*              RNA, U2 small nuclear 36, pseudogene                  4.80 × 10^−5^    0.401         −9.650 × 10^−4^   0.959
  49                        *SNORA50A (SNORA50)*    small nucleolar RNA, H/ACA box 50A                    4.84 × 10^−5^    0.475         −9.165 × 10^−4^   0.959
  50                        *SNORA40*               small nucleolar RNA, H/ACA box 40                     5.31 × 10^−5^    0.394         −1.075 × 10^−3^   0.959
  51                        *SNORD1B*               small nucleolar RNA, C/D box 1B                       8.82 × 10^−5^    0.333         −1.285 × 10^−3^   0.959

The table presents *p* (FDR with Benjamini--Hochberg correction) and fold change values received from DESeq2 analysis, PLS coefficients received from UVE-PLS analysis and areas under receiver operating characteristics (ROC) curves (ROC-AUC) received from ROC analysis. Genes were divided into upregulated and downregulated groups and ordered according to increasing *p* value. Gene symbols without assigned gene names by a Human Genome Organization (HUGO) Multi-Symbol Checker (<https://www.genenames.org/tools/multi-symbol-checker/>) were termed as "unmatched". Gene symbols in brackets are synonyms or previous gene symbols.
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###### 

Correlation analysis between maximum aneurysm diameter, thrombus volume, aneurysm neck length, age, body mass index (BMI) and expression of 33 selected miRNA transcripts and 51 selected genes identified as potential abdominal aortic aneurysm signatures. MiRNA transcripts and genes with at least one statistically significant correlation (*p* \< 0.05) were presented. All correlations results are provided in [Table S9 and S10 in Supplementary File](#app1-jcm-09-01974){ref-type="app"}.

  miRNA Transcript/Gene            Maximum Aneurysm Diameter   Thrombus Volume   Aneurysm Neck Length   Age     BMI                                                
  -------------------------------- --------------------------- ----------------- ---------------------- ------- ---------- ------- ----------- ------- ----------- -------
  hsa-mir-122_hsa-miR-122-5p       0.10                        0.619             0.27                   0.160   −0.05      0.782   0.10        0.618   −0.38 ^1^   0.045
  hsa-mir-125b-1_hsa-miR-125b-5p   0.02                        0.926             −0.19                  0.341   0.45 ^1^   0.015   0.08        0.692   −0.01       0.954
  hsa-mir-125b-2_hsa-miR-125b-5p   0.12                        0.560             −0.08                  0.686   0.40 ^1^   0.037   0.09        0.662   0.02        0.901
  hsa-mir-34a_hsa-miR-34a-5p       0.47 ^1^                    0.011             0.32                   0.096   −0.04      0.852   0.26        0.183   -0.01       0.961
  hsa-mir-3591_hsa-miR-3591-3p     0.10                        0.616             0.27                   0.160   −0.05      0.781   0.10        0.617   −0.38 ^1^   0.045
  hsa-mir-574_hsa-miR-574-5p       0.16                        0.421             0.49 ^1^               0.007   −0.03      0.896   0.26        0.180   0.16        0.414
  hsa-mir-769_hsa-miR-769-5p       −0.22                       0.252             −0.04                  0.832   0.36       0.061   −0.41 ^1^   0.032   0.01        0.973
  hsa-mir-7847_hsa-miR-7847-3p     0.33                        0.089             −0.01                  0.944   0.13       0.521   0.53 ^1^    0.003   -0.03       0.884
  *AC092620.2*                     0.32                        0.482             −0.39                  0.389   0.69       0.085   0.81 ^1^    0.028   0.19        0.688
  *GIT2*                           0.20                        0.666             −0.37                  0.415   0.64       0.120   0.27        0.563   0.81 ^1^    0.027
  *PDCD4*                          −0.14                       0.768             0.03                   0.945   −0.07      0.885   −0.81 ^1^   0.026   −0.18       0.699
  *RP1-102E24.1*                   0.30                        0.508             0.38                   0.396   0.08       0.864   −0.18       0.703   −0.78 ^1^   0.039
  *RPL3P9*                         0.05                        0.911             0.14                   0.757   −0.42      0.344   −0.17       0.713   −0.76 ^1^   0.046
  *SNHG5*                          −0.01                       0.976             0.32                   0.490   −0.22      0.633   −0.80 ^1^   0.030   −0.19       0.685
  *SUFU*                           0.48                        0.278             −0.24                  0.597   0.48       0.274   0.77 ^1^    0.041   0.41        0.357
  *ZRANB2*                         −0.35                       0.448             −0.19                  0.679   −0.21      0.649   −0.79 ^1^   0.036   0.08        0.857

R---Spearman correlation coefficient, ^1^ correlations statistically significant (*p* \< 0.05).
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###### 

Functional analysis of eighteen networked miRNA targets.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Functional Analysis of 12 Upregulated Genes (*ANKRD13D*, *CPT1A*, *GGT1*, *GIT2*, *HTT*, *NBEAL2*, *SUFU*, *THOC5*, *UBE4B*, *UPF1*, *ZSWIM8*, and *ZZEF1*)   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *ANKRD13D*                                                                                                                                                    **GAD**: Type 2 Diabetes\|edema\|rosiglitazone\
                                                                                                                                                                **GAD Class**: pharmacogenomic

  *CPT1A*                                                                                                                                                       **KEGG**: fatty acid degradation, fatty acid metabolism, PPAR signaling pathway, AMPK signaling pathway, adipocytokine signaling pathway, glucagon signaling pathway, insulin resistance\
                                                                                                                                                                **Reactome**: RORA activates gene expression, PPARA activates gene expression, import of palmitoyl-CoA into the mitochondrial matrix, signaling by retinoic acid\
                                                                                                                                                                **GAD**: acquired immunodeficiency syndrome\|disease progression, Alzheimer's disease, atherosclerosis, BMI--Edema rosiglitazone or pioglitazone, diabetes, type 2 hepatic lipid content insulin, hepatitis C, chronic, hypercholesterolemia\|LDLC levels, left ventricular hypertrophy, lipid metabolism, inborn errors\|sudden infant death, obesity, tunica media, type 2 diabetes\|edema\|rosiglitazone\
                                                                                                                                                                **GAD Class**: cardiovascular, infection, metabolic, neurological, pharmacogenomic, unknown

  *GGT1*                                                                                                                                                        **KEGG**: taurine and hypotaurine metabolism, cyan amino acid metabolism, glutathione metabolism, arachidonic acid metabolism, metabolic pathways\
                                                                                                                                                                **Reactome**: glutathione synthesis and recycling, synthesis of leukotrienes (LT) and eoxins (EX), aflatoxin activation and detoxification, defective GGT1 causes glutathionuria (GLUTH)\
                                                                                                                                                                **GAD**: aging/ telomere length, alkaline phosphatase, arsenic exposure, cognitive trait, fatty liver\|metabolic syndrome X, gamma-glutamyltransferase, liver enzymes, normal variation, pancreatic neoplasm\|pancreatic neoplasms, plasma levels of liver enzymes, protein quantitative trait loci, sleep apnea, obstructive\
                                                                                                                                                                **GAD class**: cardiovascular

  *GIT2*                                                                                                                                                        **KEGG**: endocytosis\
                                                                                                                                                                **GAD**: cholesterol, HDL, E-selectin\
                                                                                                                                                                **GAD Class**: metabolic

  *HTT*                                                                                                                                                         **KEGG**: Huntington's disease\
                                                                                                                                                                **GAD**: atrophy\|Huntington's disease, chronic progressive chorea\|, cognitive ability, cognitive function, Huntington's disease; ataxia (SCA), myotonic dystrophy type 1, null, Parkinson's disease, prostatic neoplasms, psychiatric disorders, schizophrenia, sleep disorders; Tourette syndrome, suicide\
                                                                                                                                                                **GAD Class**: cancer, neurological, other, psych, unknown

  *NBEAL2*                                                                                                                                                      **GAD**: Schizophrenia\
                                                                                                                                                                **GAD Class**: psych

  *SUFU*                                                                                                                                                        **KEGG**: hedgehog signaling pathway, pathways in cancer, Basal cell carcinoma\
                                                                                                                                                                **Reactome**: degradation of GLI1 by the proteasome, Degradation of GLI2 by the proteasome, GLI3 is processed to GLI3R by the proteasome, hedgehog 'off' state, hedgehog 'on' state\
                                                                                                                                                                **GAD**: Alzheimer's disease, head and neck neoplasms\|neoplasm recurrence, local\|neoplasms, second primary\
                                                                                                                                                                **GAD Class**: cancer, neurological

  *THOC5*                                                                                                                                                       **KEGG**: RNA transport\
                                                                                                                                                                **Reactome**: transport of mature mRNA derived from an intron-containing transcript, mRNA 3'-end processing\
                                                                                                                                                                **GAD**: carotid atherosclerosis in HIV infection\
                                                                                                                                                                **GAD Class**: cardiovascular

  *UBE4B*                                                                                                                                                       **KEGG**: ubiquitin mediated proteolysis, protein processing in endoplasmic reticulum\
                                                                                                                                                                **GAD**: arteries, carcinoma, hepatocellular\|hepatitis B, chronic\|LCC---liver cell carcinoma\|liver neoplasms\
                                                                                                                                                                **GAD Class**: cancer, cardiovascular

  *UPF1*                                                                                                                                                        **KEGG**: RNA transport, mRNA surveillance pathway\
                                                                                                                                                                **Reactome**: nonsense mediated decay (NMD) independent of the exon junction complex (EJC), nonsense mediated decay (NMD) enhanced by the exon junction complex (EJC)

  *ZSWIM8*                                                                                                                                                      **GAD**: Alzheimer's disease\
                                                                                                                                                                **GAD Class**: neurological

  *ZZEF1*                                                                                                                                                       **GAD**: tobacco use disorder\
                                                                                                                                                                **GAD Class**: chemdependency

  *Gene Ontology terms associated with EASE score \< 0.05*                                                                                                      

  GO Biological Process                                                                                                                                         Cellular catabolic process, regulation of cellular catabolic process, organic substance catabolic process, catabolic process, regulation of catabolic process, intracellular transport, positive regulation of cellular catabolic process, establishment of localization in cell, positive regulation of catabolic process, cellular response to stimulus, positive regulation of lipid catabolic process, nucleocytoplasmic transport, nuclear transport, cellular localization, cellular developmental process, regulation of lipid catabolic process, behavior, response to stimulus, single-organism intracellular transport, nitrogen compound transport, animal organ development, mRNA-containing ribonucleoprotein complex export from nucleus, mRNA export from nucleus

  GO Cellular Compartment                                                                                                                                       Membrane-bounded organelle, nucleoplasm

  **Functional analysis of 6 downregulated gene (*KIAA1549L*, *PDCD4*, *PRDM13*, *SNORA60*, *SNORD94*, and *ZRANB2*)**                                          

  *KEGG, Reactome, GAD and GAD Class*                                                                                                                           

  *KIAA1549L*                                                                                                                                                   **GAD**: alcoholism, body height, creatinine, heart rate, suicide, attempted\
                                                                                                                                                                **GAD Class**: cardiovascular, chemdependency, developmental, metabolic, psych

  *PDCD4*                                                                                                                                                       **KEGG**: proteoglycans in cancer, microRNAs in cancer\
                                                                                                                                                                **GAD**: Alzheimer's disease, longevity\
                                                                                                                                                                **GAD Class**: aging, neurological

  *PRDM13*                                                                                                                                                      **GAD**: menarche, Parkinson's disease\
                                                                                                                                                                **GAD Class**: neurological, reproduction

  *SNORA60*                                                                                                                                                     No information

  *SNORD94*                                                                                                                                                     No information

  *ZRANB2*                                                                                                                                                      No information

  *Gene Ontology terms associated with EASE score \<0.05*                                                                                                       

  GO Biological Process                                                                                                                                         Regulation of transcription, DNA-templated, regulation of nucleic acid-templated transcription, regulation of RNA biosynthetic process, regulation of RNA metabolic process, nucleic acid-templated transcription, RNA biosynthetic process, regulation of cellular macromolecule biosynthetic process, regulation of nucleobase-containing compound metabolic process, regulation of macromolecule biosynthetic process, regulation of cellular biosynthetic process, regulation of biosynthetic process, regulation of gene expression, nucleobase-containing compound biosynthetic process, regulation of nitrogen compound metabolic process, heterocycle biosynthetic process, aromatic compound biosynthetic process, organic cyclic compound biosynthetic process, RNA metabolic process, cellular nitrogen compound biosynthetic process, cellular macromolecule biosynthetic process, nucleic acid metabolic process, macromolecule biosynthetic process, gene expression

  GO Molecular Function                                                                                                                                         Nucleic acid binding
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Analysis was performed using DAVID 6.8 database and following categories: Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, Genetic Association Database (GAD), Genetic Association Database Class (GAD Class) and Gene Ontology (GO).
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###### 

The most relevant studies regarding differentially expressed miRNAs in abdominal aortic aneurysm (AAA), with results overlapping findings of the current study.

  Ref.                      Cases vs Controls                        Material                    Method (Number of Differentially Expressed miRNAs)   MiRNAs Overlapping with miRNA Biomarkers Proposed in the Current Study
  ------------------------- ---------------------------------------- --------------------------- ---------------------------------------------------- ----------------------------------------------------------------------------------
  \[[@B42-jcm-09-01974]\]   6 AAA subjects vs 6 controls             Abdominal aorta tissues     qPCR (59)                                            let-7g-3p, miR-454-3p, -24-3p, -31-5p, -125b-5p, -150-5p, -99a-3p
  \[[@B43-jcm-09-01974]\]   169 AAA subjects vs 48 controls          Plasma                      qPCR (103)                                           miR-454-3p, -122-5p, -424-5p, -766-3p
  \[[@B44-jcm-09-01974]\]   15 AAA subjects vs 10 non-AAA controls   Whole blood samples         qPCR (29)                                            miR-125b-5p, -138-5p
  \[[@B45-jcm-09-01974]\]   10 AAA subjects vs 10 controls           Plasma                      Microarray (151)                                     miR-21-5p, -574-5p, -24-3p, -122-5p, -31-5p, -342-3p, -150-5p, -125b-5p, -339-3p
  \[[@B46-jcm-09-01974]\]   5 AAA subjects vs 5 controls             Infrarenal aortic tissues   Microarray (8)                                       miR-21-5p

The table presents studies on miRNAs in AAA. Differentially expressed miRNAs are revealed from AAA subjects and control groups. MiRNAs overlapping with biomarkers proposed in the current study are shown. For more comprehensive review of this topic please refer to \[[@B26-jcm-09-01974]\].

[^1]: D.P.Z. and K.P.R. shared first authorship.

[^2]: M.F., J.K. and A.B.-K shared senior authorship.
